Accéder au contenu
Merck

Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies.

Antiviral research (2023-07-15)
Xin Zhang, Niels Cremers, Stijn Hendrickx, Yannick Debing, Tania Roskams, Lotte Coelmont, Johan Neyts, Suzanne J F Kaptein
RÉSUMÉ

The hepatitis E virus (HEV) is a major cause of hepatitis, with an estimated 3.3 million symptomatic cases annually. There is no HEV-specific treatment besides the off-label use of ribavirin and a vaccine is only available in China and Pakistan. To aid the development of therapeutic and preventive strategies, there is a need for convenient HEV infection models in small laboratory animals. To this end, we make use of the rat hepatitis E virus. Human infections with this virus have been reported in recent years, making it a relevant pathogen for the establishment of a small animal infection model. We here report that oral gavage of a feces suspension, containing a pre-defined viral RNA load, results in a reproducible synchronized infection in athymic nude rats. This route of administration mimics fecal-oral transmission in a standardized fashion. The suitability of the model to study the effect of antiviral drugs was assessed by using ribavirin, which significantly reduced viral loads in the feces, liver, and other tissues.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-virus de l'hépatite E (a.a. 434-457), clone 1E6, clone 1E6, Chemicon®, from mouse